OTCMKTS:SBMFF - Sino Biopharmaceutical Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.69
▲ +0.01 (1.48%)

This chart shows the closing price for SBMFF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sino Biopharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBMFF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBMFF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.69.

This chart shows the closing price for SBMFF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Sino Biopharmaceutical. This rating has held steady since October 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2020Daiwa Capital MarketsInitiated CoverageBuy
8/20/2020MacquarieDowngradeOutperform ➝ Neutral
5/12/2020Sanford C. BernsteinUpgradeUnderperform ➝ Market Perform
3/19/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
4/18/2017Jefferies Financial GroupInitiated CoverageUnderperform
(Data available from 12/9/2016 forward)

News Sentiment Rating

-0.58 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/11/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sino Biopharmaceutical logo
Sino Biopharmaceutical Limited, an investment holding company, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates in three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Qingkeshu tablets, Qianping injections, Anxian capsules, Yinishu tablets, Genike capsules, Shoufu tablets, Jizhi tablets, and Leweixin injection; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, Sacubatro/Valsartan tablets, Tolvaptan tablets, Rivaroxaban tablets, Edaravone injections, Esmolol Hydrochloride injections, Esmolol Hydrochloride and Sodium Chloride injections, Polidocanol injections, Sacubitril Valsartan Sodium tablets, Urapidil Hydrochloride injections, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules, Taiyan tablets, Zoledronic Acid injections, and Yigu injections. Its principal products also comprise digestive system medicines that consists of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tianjie injections, Fengruineng injections, Tianli injections, and Tianming injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms, and Qingliming injections. In addition, the company engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, it manufactures, sells, and distributes health food; and develops medical technology. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Read More

Today's Range

Now: $0.69
Low: $0.69
High: $0.69

50 Day Range

MA: $0.74
Low: $0.68
High: $0.83

52 Week Range

Now: $0.69
Low: $0.68
High: $1.21

Volume

894 shs

Average Volume

6,866 shs

Market Capitalization

$12.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Sino Biopharmaceutical?

The following Wall Street analysts have issued research reports on Sino Biopharmaceutical in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for SBMFF.

What is the current price target for Sino Biopharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Sino Biopharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sino Biopharmaceutical in the next year.
View the latest price targets for SBMFF.

What is the current consensus analyst rating for Sino Biopharmaceutical?

Sino Biopharmaceutical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBMFF.

How do I contact Sino Biopharmaceutical's investor relations team?

Sino Biopharmaceutical's physical mailing address is Rm 4109 Office Tower Convention Plaza 1 Harbour Road Wanchai, Hong Kong K3, . The company's listed phone number is 852-2802-9886 and its investor relations email address is [email protected] The official website for Sino Biopharmaceutical is www.sinobiopharm.com.